A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
ClinicalTrials.gov ID
NCT02061683
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
263Actual
Last Update Posted
Apr 18, 2019Actual
Start Date
Apr 19, 2010Actual
Primary Completion Date
Jun 24, 2011Actual
Completion Date
Jun 24, 2011Actual
Brief Summary
This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension.
Glaucoma, Open-Angle
Ocular Hypertension
Bimatoprost 0.03%
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of open-angle glaucoma or ocular hypertension
No use of Lumigan® in the past 3 months
Exclusion Criteria:
Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months